Clearmind Medicine
CMND
5 hedge funds and large institutions have $137K invested in Clearmind Medicine in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 0 reducing their positions, and closing their positions.
150% more funds holding
Funds holding: 2 → 5 (+3)
24.76% more ownership
Funds ownership: 9.94% → 34.7% (+25%)
19% more capital invested
Capital invested by funds: $115K → $137K (+$21.7K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$147K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$73.3K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$36.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$8K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$5.87K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.94K |
| 4 |
ODG
O'Dell Group
Cincinnati,
Ohio
|
-$9 |
CMND Hedge Fund Activity: Q3 2023 in Review
5 of the 6,313 institutional investors tracked by Wall St. Rank reported a position in Clearmind Medicine (CMND) for Q3 2023, worth a combined $137K — up 19% from $115K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CMND positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Walleye Capital, opening a new position worth an estimated $147K. The largest seller was HRT Financial, cutting an estimated $8K.
- 5 institutional investors held Clearmind Medicine (CMND) as of Q3 2023, up from 2 in Q2 2023.
- Funds reported $137K of Clearmind Medicine stock for Q3 2023, up 19% quarter-over-quarter.
- 3 funds opened new Clearmind Medicine positions in Q3 2023 and 0 closed out, a net change of +3 holders.
- The largest Clearmind Medicine buyer in Q3 2023 was Walleye Capital, an estimated $147K added.
- The largest Clearmind Medicine seller in Q3 2023 was HRT Financial, an estimated $8K sold.
Based on aggregated 13F filings for Q3 2023.